Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells

XIAOPO HE1,2, YIRAN LIU3, KAI LI1,4, AIJUN YANG5, RUI WANG1,4 and SHAOHUA LIU4

1School of Stomatology, Shandong University, Jinan, Shandong 250012; 2Department of Oral and Maxillofacial Surgery, Weifang People’s Hospital, Weifang, Shandong 261041; 3School of Medicine, Shandong University; 4Department of Oral and Maxillofacial Surgery, Qilu Hospital, Shandong University; 5Library of Shandong University, Jinan, Shandong 250012, P.R. China

Received August 11, 2015; Accepted December 9, 2016

DOI: 10.3892/etm.2017.4306

Abstract. Treatment of infantile hemangiomas (IH) with propranolol was first reported in 2008. Regressions of lymphatic malformations combined with pulmonary hypertension was first reported in 2012 after three children received treatment with oral sildenafil, which as an antagonist of phosphodiesterase isoform-5 (PDE-5). Inhibition of endothelial cells in the cytoplasm of IH tissues was obtained in our previous study. Therefore, the present study hypothesized that the antagonist of PDE-5, sildenafil, may lead to the regression of hemangiomas. To assess this hypothesis, the proliferation and apoptosis of specimen-derived hemangioma endothelial cells (HemECs) was determined in vitro by an MTT assay and flow cytometry, respectively, following treatment with sildenafil. The potential mechanisms underlying the mRNA and protein expression levels of inhibitor of differentiation 1 (Id-1) were determined by reverse transcription-quantitative polymerase chain reaction and western blotting. The results demonstrated that 5 µM sildenafil suppressed the proliferation of HemECs and significantly enhanced the rate of apoptosis after 24 h. Additionally, the mRNA and protein expression levels of Id-1 were downregulated following treatment with sildenafil. Therefore, the present study concluded that PDE-5 may be a potential therapeutic target for hemangiomas and Id-1 may serve a vital role in the associated signaling transduction pathways.

Introduction

Infantile hemangioma (IH), pathologically diagnosed as immature vascular endothelial cell proliferation (1), is the most common benign neoplasm of infancy and occurs in ~4% of children (2). IH is well known for its rapid growth within the first month after birth, followed by a spontaneous and slow involution. Early intervention is recommended for IH due to the potential disfigurement, dysfunction and psychosocial impairment that may occur (3,4). Currently, oral propranolol is the first-line therapy for IH, which acts by inducing rapid and substantial regression of the lesions with minimal adverse effects (5,6), and results in the occasional successful treatment of IH (7).

In 2012, Swetman et al (8) reported an occasional regression of lymphatic malformation (LM) combined with pulmonary hypertension in three children following treatment with oral sildenafil, which served as an antagonist of phosphodiesterase isoform 5 (PDE-5) (8). Inhibition of PDE-5 decreased the contractility of vascular smooth muscle followed by cystic decompression, which potentially explained the therapeutic effects of sildenafil in LM (8). Based on this previous finding, in the current study, tissue sections were selected from patients with LM and IH, and subjected to immunohistochemistry (IHC) testing to confirm the expression of PDE-5 in LM. The results from IHC analysis revealed that PDE-5 was expressed in the cytoplasm of endothelial cells in IH, but not expressed in the endothelium of patients with LM. According to these results of the current study, it was hypothesized that as an antagonist of PDE-5, sildenafil, may facilitate the regression of hemangiomas, as it is similar to propranolol. To assess this hypothesis, the proliferation and apoptosis of specimen-derived hemangioma endothelial cells (HemECs), following treatment with sildenafil in vitro and its potentially associated mechanisms, were investigated via MTT assay and flow cytometry. The potential mechanisms underlying the mRNA and protein expression levels of inhibitor of differentiation 1 (Id-1) were determined by reverse transcription-quantitative polymerase chain reaction and western blotting.

Materials and methods

Specimens of vascular anomalies. Formalin-fixed and paraffin-embedded specimens of vascular anomalies for IH
were obtained randomly from the Department of Pathology of Qilu Hospital (Shandong University, Jinan, China) between January 2000 and December 2013. Specimens were from 20 patients; 8 males and 12 females, aged 4 months-39 years (mean, 5 years). Patients were included if they had undergone no other treatments, such as drug therapy, laser therapy, and cryotherapy, in the past but were excluded if they presented with infection, systemic diseases, had undergone sclerotherapy or had a history of drug use. Specimens included lymphatic malformations (n=10), proliferating hemangiomas (n=8), and involving hemangiomas (n=2). The diagnosis of these anomalies was confirmed by patient medical histories, physical examinations, magnetic resonance imaging (MRI) and final pathological examinations. The present study was approved by Qilu Hospital Ethics Committee of Shandong University and all the patients provided their written informed consent.

**Expression of PDE-5 in vascular anomalies.** Paraffin-embedded 4-µm serial tissue sections were obtained and IHC was performed to assess the expression of PDE-5 in different types of vascular anomalies using an ABC kit (Gene Tech Co., Ltd., Shanghai, China). Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), cluster of differentiation 34 (CD34) and glucose transporter-1 (GLUT-1) were used as markers for lymphatic endothelial cells, vascular endothelial cells and hemangioma tissues, respectively, to confirm the type of vascular anomalies. Subsequently, the expression of PDE-5 was assessed in the tissues of all the vascular anomalies.

Tissue sections were deparaffinized in xylene (Guangcheng Chemical Reagent Co., Ltd., Tianjin, China) and rehydrated in graded alcohol, followed by three rinses (each for 5 min) in phosphate-buffered saline (PBS). Endogenous peroxidases were quenched by incubating the tissue sections with 10% (v/v) methanol and 3% (v/v) hydrogen peroxide for 15 min at room temperature. A citrate buffer solution (10 mM; pH 6.0; Beijing Solarbio Life Sciences Co., Ltd., Beijing, China) was used to unmask antigens at 100˚C for 15 min, rehydrated in graded alcohol, followed by three rinses (each for 5 min) in PBS and cut into pieces 1cmx1cmx1 cm large. The residue was maintained to estimate the expression of GLUT-1, which served as the molecular marker for hemangioma.

**Isolation and cultivation of HemECs.** A specimen of proliferating hemangioma was obtained from a 3-month-old female by surgical resection and was confirmed by pathological examinations in the Department of Oral & Maxillofacial Surgery of Qilu Hospital, Shandong University. Tissue samples were rinsed with PBS and cut into pieces 1cmx1cmx1 cm large. The majority of the pieces were used for culturing HemECs and the residue was maintained to estimate the expression of GLUT-1, which served as the molecular marker for hemangioma.

**Immunocytochemistry.** HemECs were isolated from adherent tissue and the expression levels of CD34, von Willebran factor (vWF) and PDE-5 were determined by immunocytochemistry. Cells (5.0x10^5 cells/well) were seeded in gelatin-coated 24-well plates in endothelial basal medium (EBM-2; Lonza Inc., Allendale, NJ, USA), supplemented with 20% heat-inactivated fetal bovine serum (Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA), single growth medium (Lonza Inc.), penicillin (100 U/ml) and streptomycin (100 µg/ml; both Gibco; Thermo Fisher Scientific Inc.). Isolated cells were cultivated in a humidified and sterilized incubator, in an atmosphere containing 5% CO2, at 37˚C. Fresh medium was added following removal and washing of the initial medium was performed every 2-3 days. All experiments were performed using endothelial cells between generations three and five.

**Viability of HemECs after sildenafil treatment.** An MTT assay was used to assess the effects of sildenafil on the viability of HemECs. Sildenafil (Selleck Chemicals; Houston, TX, USA) stock solution at 100 µM was prepared by dissolving sildenafil in dimethyl sulfoxide (DMSO) and was stored at 4˚C. HemECs were seeded in 96-well plates (5.0x10^5 cells/well) and were cultivated in EBM-2, containing all the supplements mentioned, for 24 h with five replicates per concentration. The medium was subsequently changed to serum-free EBM-2 for another 24 h. The medium was replaced with 200 µl fresh medium, containing increasing concentrations of sildenafil (0, 1, 3, 5, 10 and 15 µM) and cultured for different durations (24, 48 and 72 h). Cells in the control groups (0 µM sildenafil) were cultivated in the medium with 0.1% DMSO and cultured for different durations (24, 48, and 72 h). Cells in the control groups (0 µM sildenafil) were cultivated in the medium with 0.1% DMSO (sildenafil-free medium). Following treatment, HemECs were incubated with MTT (20 µl/well) for 4 h at 37˚C, and the optical density at 490 nm was measured after the cell contents were dissolved in DMSO. Absorbance was measured using an automatic microplate reader (BioTek Instruments, Inc., Winooski, VT, USA), and a minimal effective concentration and duration was calculated for late apoptosis and the expression of Id-1.

**Apoptosis of HemECs by sildenafil.** Following treatment with 0 and 5 µM sildenafil for 24 h, HemECs (1x10^5 clones) were trypsinized, rinsed with cold PBS and blended in binding buffer using the Annexin V-fluorescent isothiocyanate (FITC)/propidium iodoide (PI) Apoptosis Detection kit
Total RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). HemECs were exposed to 0 and 5 µM sildenafil for 24 h. Total RNA in HemECs was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific Inc.) and the Id-1 RNA was reverse transcribed into cDNA using a PrimeScript RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China). cDNA was amplified by PCR using specific primers for Id-1 (GeneChem Co., Ltd.-Shanghai, China): Forward, 5'-CAT TCT GTT TCA CAA AGC G-3' and reverse, 5'-CTGCCCTTAATGTACGCACCAGTTT-3'. Amplification conditions were as follows: 35 cycles at 95°C for 30 sec, 57°C for 30 sec, 72°C for 30 sec, and 72°C for 5 min, using SYBR-Green I dye real-time fluorescent quantitative detection (Takara Biotechnology Co., Ltd.) on a Mastercycler ep realplex assay system (Eppendorf; Hamburg, Germany). A primer pair for β-actin (Genechem) was used as an internal control: Forward, 5'-GTGGGGCGCCCCCCAGGACCACCA-3' and reverse, 5'-CTCCCTTAATGTACGCACCAGTTT-3'. Differences in the threshold cycles between the target genes and the reference gene (β-actin) were calculated. The value of the relative mRNA quantity for the control group was arbitrarily set to one for normalization and the data were analyzed using the comparative Cq method (2^ΔΔCq) (9).

Total protein extraction and western blotting. HemECs were exposed to 0 and 5 µM sildenafil for 24 h, and were collected for protein extraction using radio immunoprecipitation assay lysis buffer/phenylmethanesulfonyl fluoride (100:1; Beijing Solarbio, Beijing, China). Protein concentration was determined using the Micro BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Protein samples were separated using an SDS-PAGE gel kit (15% separating gel and 5% stacking gel; CoWin Biotech, Beijing, China) and were electrophoretically transferred onto a nitrocellulose membrane (Wuhan Boster Biological Technology Co., Ltd., Wuhan, China). Blocking with 5% non-fat milk for 1 h at room temperature, the membrane was incubated with the following antibodies: Anti-rabbit Id1 polyclonal IgG (sc-488; 1:400; Santa Cruz Biotechnology, Inc.) and anti-mouse β-actin polyclonal antibody (TA-09; 1:1,000; Beijing Zhongshan Jinqiao Biological Technology Co., Ltd., Beijing, China) in Tris-buffered saline containing Tween-20 [TBST; 10 mM Tris (pH 7.4), 138 mM NaCl and 0.05% Tween-20] at 4°C overnight. Subsequently, the membrane was washed with TBST three times and incubated with the appropriate secondary antibody: Goat anti-rabbit IgG conjugated to horseradish peroxidase (ZB-2301; 1:3,000; Beijing Zhongshan Jinqiao Biological Technology Co., Ltd) or goat anti-mouse IgG (GAM0041; 1:4,000; Lianke Biotech Co., Ltd., Hangzhou, China), for 1 h at room temperature. Immunopositive bands were examined using an enhanced chemiluminescence (ECL) detection system FluorChem Q (Alpha Innotech Corp., San Leandro, CA, USA) and an ECL kit (EMD Millipore, Billerica, MD, USA). Images were captured on X-ray film, according to the instructions of FluorChem Q. A human TCA 8113 tongue squamous cell carcinoma cell line (American Type Culture collection, Manassas, VA, USA) was used as a positive control for the protein expression of Id-1 (10).

**Statistical analysis.** The SPSS 20.0 software package (IBM SPSS, Armonk, NY, USA) was used to analyze the data and all the figures were generated by GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, California, USA). Paired data from the two groups were analyzed using a paired Student's t test. Repeated measurement data with two variances, two-way analysis of variance was used and an intergroup t-test was applied. P<0.05 was considered to indicate a statistically significant difference and data are expressed as the mean ± standard error of the mean.

**Results**

**PDE-5 is expressed in the cytoplasm of endothelial cells of hemangiomas.** CD34, LYVE-1 and GLUT-1 were considered as positive markers for vascular endothelial cells, lymphatic malformation endothelial cells and hemangiomas endothelial cells, respectively (11-13). Expression levels of PDE5 demonstrated that the expression of PDE5 was present in the cytoplasm of endothelial cells of hemangiomas, but not in the lymphatic malformation endothelia (Fig. 1).

**Sildenafil suppresses the viability of HemECs.** Specimen-derived HemECs were identified using vWF and CD34 markers, and positive expression of PDE-5 was also determined (Fig. 2). Viability of HemECs was determined via MTT assay following treatment with sildenafil (0, 1, 3, 5, 10 or 15 µM) for different durations (24, 48 and 72 h). As the concentration increased, the suppressive effects gradually increased in a dose-dependent manner (Fig. 3A). It was demonstrated that 5 µM sildenafil exerted significant suppressive effects on the viability of HemECs following incubation for 24 h, compared with the control group (0 µM sildenafil; t=3.220, "P<0.01; Fig. 3B). However, insignificant suppression of viability was observed in HemECs treated with 10-15 µM sildenafil (P>0.05). Therefore, the present study considered 5 µM and 24 h to be the minimal effective concentration and duration of sildenafil treatment, respectively, for the optimal suppression of HemECs.

**Sildenafil enhances the apoptosis of HemECs.** Following treatment with 5 µM sildenafil for 24 h, the morphology of HemECs changed, indicated by the destruction of intercellular junctions and increasing particles in the cytoplasm observed under light microscopy (Fig. 3C). Results of the FITC-PI labeled flow cytometric analysis demonstrated a higher apoptosis rate of 10.5% compared with 2.53% in the control group (Fig. 3D).

**Sildenafil downregulates the mRNA and protein expression levels of Id-1.** Following treatment with 5 µM sildenafil for
HE et al: SILDENAFIL REGULATES PROLIFERATION AND APOPTOSIS IN HEMANGIOMA ENDOTHELIAL CELLS

Discussion

Infantile hemangioma is a common benign vascular tumor that is distinctive for its perinatal presentation, rapid growth during the first year of life and subsequent involution (14); although, the pathogenesis remains to be elucidated, the predominant theory is that abnormal EC (HemECs) proliferation triggers dysregulation of angiogenesis with high expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor during the proliferative phase (15). Gradual changes in the proliferation and apoptosis of HemECs occur between the proliferating and involuting phases (16). Determining the precise cellular mechanisms that drive hemangioma growth and apoptosis will provide a basis for targeted therapies to inhibit the proliferating phase or accelerate the involuting phase, in order to cure hemangiomas.

PDE-5 is a subtype of the PDE family, which preferentially hydrolyzes cyclic guanosine monophosphate (cGMP) and is abundant in vascular smooth muscle cells (17). Previously, PDE-5 was implicated in the proliferation and apoptosis of pulmonary ECs and cancer cells (18–20). Sildenafil, as an antagonist of PDE-5, has been widely applied to treat pulmonary hypertension and erectile disorders (21–23). To the best of our knowledge, the present study revealed for the first time that PDE-5 was expressed in HemECs. In addition, it was demonstrated that sildenafil exerted a significant proliferative suppression effect on HemECs in vitro. These findings are consistent with results published by Erdogan et al (24), in which sildenafil significantly suppressed the proliferation of human umbilical vein endothelial cells.

Distinct from that of necrosis, apoptosis is the process of programmed cell death that has been regarded as a recommended and privileged strategy for clearing tumor cells. Apoptosis of HemECs increased by 5-fold in the involuting phase compared with that in the proliferating phase in a previous study (16). Therefore, a strategy that triggers apoptosis in HemECs may be an effective treatment for hemangiomas. PDE-5 inhibitors have been demonstrated to induce apoptosis in human breast tumor cells by increasing cGMP levels (25). The present study revealed that treatment with 5 µM sildenafil for 24 h markedly increased the ratio of apoptotic HemECs labeled with Annexin V-FITC/PI, as determined by flow cytometry. This suggested that PDE-5 may contribute to revealing the pathogenesis of hemangiomas, and its antagonists may be considered as novel drug candidates for the treatment of hemangioma.

Id-1 is an important subfamily member of the helix-loop-helix proteins. Increased expression levels of Id-1 have been implicated in regulating the growth, proliferation, migration and differentiation of cells (10,26). Additionally, Id-1 promoted the proliferation and survival of endothelial progenitor cells (27). Knockdown of Id-1 with RNA interference abolished proliferation, activation, and angiogenic processes of human umbilical vein endothelial cells (HUVECs) induced by VEGF (28). In the present study, following treatment with 5 µM sildenafil for 24 h, the mRNA and protein expression levels of Id-1 in HemECs markedly decreased. These findings indicated proliferative suppression by sildenafil was exhibited in HemECs via the regulation of...
Id-1 expression. It has been reported that PDE-5 inhibitors reduced the expression of VEGF in a rat model of cyclosporine-induced nephrotoxicity (29). We therefore considered that sildenafil can reduce the VEGF-induced angiogenic processes in hemangioma by downregulation of Id-1 to lead to hemangioma regression.

In conclusion, the present findings demonstrated that PDE-5 was expressed in hemangioma tissues, and its antagonist, sildenafil, has the ability to suppress the proliferation and induce apoptosis of HemECs in vitro. Id-1 is important in this process, although further studies are required to elucidate the cellular and molecular mechanisms that occur. It is essential that future in vivo hemangioma animal model studies are performed to investigate the effectiveness of sildenafil, prior to it being introduced into clinical practices.

Acknowledgements

The authors would like to thank the Institute of Dental Medicine of Qilu Hospital, Shandong University for technical assistance. The present study was supported by the National Natural Science Foundation of China (grant...
References

1. Mulliken JB and Glowacki J: Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg 69: 412-422, 1982.

2. Greenberger S and Bischoff J: Pathogenesis of infantile haemangioma. Br J Dermatol 169: 12-19, 2013.

3. Cohen-Barak E, Rozenman D and Shani Adir A: Infantile haemangiomas and quality of life. Arch Dis Child 98: 676-679, 2013.

4. Zweegers J and van der Vleuten CJM: The psychosocial impact of an infantile haemangioma on children and their parents. Arch Dis Child 97: 922-926, 2012.

5. Léauté-Labrèze C, Dumas de la Roque E, Naka F, Abouelfath A, Grenier N, Rebola M, Ezzedine K and Moore N: Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants <4 months of age. Br J Dermatol 169: 181-183, 2013.

6. Fabian ID, Ben-Zion I, Samuel C and Spierer A: Reduction in astigmatism using propranolol as first-line therapy for periocular capillary haemangioma. Am J Ophthalmol 151: 53-58, 2011.

7. Léauté-Labrèze C, Dumas dela Roque E, Hubiche T, Boralevi F, Thambo JB and Tatieb A: Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2689-2691, 2008.

8. Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT and Bruckner AL: Sildenafil for severe lymphatic malformations. N Engl J Med 366: 384-386, 2012.

9. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408, 2001.

10. Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y and Liu S: Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol 47: 27-32, 2011.

11. Martin-Padura I, De Castellarnau C, Uccini S, Pilozzi E, Natali PG, Nicotra MR, Ughi F, Azzolini C, Dejana E and Ruco L: Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. Pathol 175: 51-57, 1995.

12. Heinzelmekker K, Kemf KM, Kurz K, Steidler A, Weiss C, Jackson DG, Bolenz C, Haeccker A and Trojan L: Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelial cell markers D2-40 and LYVE-1: Correlation with pathologic parameters and clinical outcome. Urol Oncol 31: 1386-1394, 2013.

13. North PE, Waner M, Mizeracki A and Mihm MC Jr: GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31: 11-22, 2000.

14. Metry D: Update on hemangiomas of infancy. Curr Opin Pediatr 16: 373-377, 2004.

15. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J and Ezekowitz RA: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93: 2357-2364, 1994.

16. Frieden JJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Basgelia E, Garzon MC, Nopper AJ, et al: Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 22: 383-406, 2005.

17. Lin CS: Tissue expression, distribution, and regulation of PDE5. Int J Implant Res 16 Suppl 1: S8-S10, 2004.

18. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklin AP, Phillips SC and Wilkins MR: Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105-113, 2005.

19. Zhu B, Strada S and Stevens T: Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289: L196-L206, 2005.

20. Kummerle M, Sugihara K, Tsukamoto S, Huang Y, Tsudorome Y, Suzuki T, Suenasu Y, Ueda N, Yamashita S, Kim Y, et al: 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest 123: 787-799, 2013.

21. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD and Zapol WM: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92: 1702-1712, 2000.

22. Kukreja RC, Salloum FN, Das A, Koka S, Ockaili RA and Xi L: Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol 16: e30-e35, 2011.

23. Bivalacqua TJ, Champion HC, Hellstrom WJ and Kadowitz PJ: Pharmacotherapy for erectile dysfunction. Trends Pharmacol Sci 21: 484-489, 2000.

24. Erdogan A, Lucdders DW, Muenz BM, Schaefer CA, Tillmanns H, Wieche J and Kuhlmann CR: Sildenafil inhibits the proliferation of cultured human endothelial cells. Int J Biomed Sci 3: 93-96, 2007.

25. Tinsley RN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC and Piazza GA: Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 8: 3331-3340, 2009.

26. Hui CM, Cheung PY, Ling MT, Taso SW, Wang X, Wong YC and Cheung AL: Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int J Cancer 119: 508-514, 2006.

27. Wang H, Yu Y, Guo RW, Shi YK, Song MB, Chen JF, Yu SY, Yin YG, Gao P and Huang L: Inhibitor of DNA binding-1 promotes the migration and proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem 335: 19-27, 2010.

28. Sakurai D, Tsuchiyu N, Yamaguchi A, Okaji Y, Tsuno N, Kobata T, Takahashi K and Tokunaga K: Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-induced activation and angiogenic processes of human endothelial cells. J Immunol 173: 5801-5809, 2004.

29. Yang JW, Han ST, Kim YS, Song SH, Kim BR, Eom MS, Jung SH, Choi SO and Han BG: Effects of a cGMP-specific phosphodiesterase inhibitor on expression of endothelial nitric oxide synthase and vascular endothelial growth factor in rats with cyclosporine-induced nephrotoxicity. Transplant Proc 42: 4625-4632, 2010.